Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Maximising cancer treatment and research through omics, data sharing, and open science

London Global Cancer Week 2022

Published: 20 Dec 2022

Views: 35

Rating:

Save

Dr Simon Parker - Data protection co-ordinator at the German Human Genome-phenome Archive

Dr Simon Parker speaks to ecancer about how omics, data sharing, and open science are being used to enhance cancer treatments and research.

He also covers how these resources are used in lower-middle-income countries and expands to discuss the future in global data sharing.

Related Videos

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

The use of IORT at Universitätsmedizin Mannheim hospital

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in...

Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours ( Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA )

More from ecancer